Pharmaceuticals, Biotechnology and Life Sciences
Faron Pharmaceuticals’s CEO Markku Jalk said it was disappointing to learn about the magnitude of steroid use in the patient population as RAAA is considered as a traumatic condition and to have only limited inflammatory impact on disease development.
Faron Pharmaceuticals has received Fast Track designation from the US Food and Drug Administration (FDA) for Traumakine, which also has…
Faron Pharmaceuticals said Friday that Independent Data Monitoring Committee (the IDMC) has recommended that the Interest trial for Traumakine should continue as planned with no changes, consistent with the previous four IDMC recommendations. Faron said it expects to recruit 300 patients during the fourth quarter of 2017.
Faron Pharmaceuticals has received the Independent Data Monitoring Committee’s (IDMC) recommendation to continue the INTEREST Phase III study for the treatment of patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS) with its lead product Traumakine.
Finish patent office has accepts Faron’s new formulation for a respiratory orphan disease ARDS
Faron Pharmaceuticals (Faron), the clinical stage biopharmaceutical company, has recruited the first patient in the Japanese Phase III pivotal clinical trial for the…